Development news....
Millions will fast-track vaccines
U of S expecting federal research funds
Lana Haight, The StarPhoenix
Published: Friday, February 15, 2008
The
University of Saskatchewan is in line for almost $15 million in federal money to fast-track the development of life-saving vaccines.
"We really want to fill a gap," said Andy Potter, director of the university's Vaccine and Infectious Disease Organization (VIDO)/InterVac.
Between $80 million and $100 million is spent each year in Canada researching potential vaccines, yet the money doesn't result in the production of a lot of new vaccines.
"Vaccine research is expensive and a high-risk area," said Potter.
VIDO is taking the lead in setting up a new national non-profit research corporation called the Pan-Provincial Vaccine Enterprise (PREVENT) designed to bridge the gap that exists between the country's university laboratories and the commercial development of vaccines.
The U of S was one of 25 organizations to submit proposals that were considered by the federal government to receive funding as a National Centre of Excellence for Commercialization and Research. On Thursday, the government announced 11 organizations that will each receive $14.95 million over five years.
"This represents a very, very strong judgment on the part of the peer-reviewing authorities that this centre does outstanding work and is the logical place to locate a centre that is specializing in vaccines," said U of S president Peter MacKinnon.
"This is a very important development not only for VIDO/InterVac, but is an
illustration of the great strength existing in potential at this university. It's a very positive development," he said.
The new vaccine research corporation will receive an additional $10.5 million over five years in in-kind support from the U of S as well as two partners: The Canadian Centre for Vaccinology, based in Halifax, N.S., and the B.C. Centre for Disease Control. The in-kind support will include providing research and office space as well as support services.
At the top of the new organization's agenda is to seek input from public health experts to determine which new vaccines are needed to deal with disease in Canada, said Potter, the interim CEO of the corporation.
The list of possibilities is long: Pandemic influenza, whooping cough, measles, chlamydia, "mad cow" disease and severe diarrheal diseases.
Currently, about a couple of dozen vaccines have been developed in labs, but they haven't gotten past the initial research stage.
"We will evaluate a whole bunch of them. There has to be a market for it from the public health system and there has to be a desire by industry to produce it," said Potter.
"We're not interested in competing with industry. If there's something they're doing right now and they're doing well, we're not going to get involved in that space at all."
Potter says the new research organization will drive Canada's vaccine research agenda. Canada is, and always has been, a world leader in vaccine development, but there's a problem.
"The research is very fragmented. There's lots of little (research projects) all over the place. I would hope that PREVENT might be able to help draw some of these together because if we keep on working as individual little units, as a country, I don't think we're going to go very far," he said.
Once it's determined which vaccines ought to be developed, PREVENT will oversee early research and initial clinical trials to prove that a product is safe and to show that it works in a controlled setting.
"We want to help industry by making the proposition of making a vaccine a lot less risky and a lot less expensive," said Potter.
The first instalment of federal money should be received as early as next month, says Potter.
At least 12 people will be hired to run the new organization and to conduct research in Saskatoon. Not all of the money will stay in the city, though, as organizations in other parts of Canada are better suited for some of the work that will be needed, says Potter.
[email protected]
Source